Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0114-0006 · 4 trials · 5 indications
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).
| Arm | Type | Description |
|---|---|---|
| NNC0114-0006 + Liraglutide | EXPERIMENTAL | - |
| NNC0114-0006 + Placebo | EXPERIMENTAL | - |
| Liraglutide + Placebo | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| NNC0114-0006 | EXPERIMENTAL | - |
| Active | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NNC0114-0006 | DRUG | NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment |
| liraglutide | DRUG | Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment |
| placebo | DRUG | Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment |
Inclusion Criteria: * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * T1DM (type 1 diabetes mellitus) (as diagnosed clinically) for not...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NNC0114-0006 is an investigational small molecule being developed by Novo Nordisk for inflammatory conditions and diabetes. It has been studied in clinical trials for rheumatoid arthritis, Crohn's disease, and type 1 diabetes mellitus. The drug is not approved and remains in clinical development.
NNC0114-0006 is developed by Novo Nordisk A/S, a pharmaceutical company traded on the New York Stock Exchange under the ticker NVO. The company has sponsored multiple clinical trials evaluating the drug across inflammatory and metabolic indications.
NNC0114-0006 has completed Phase 2 clinical trials. It has been evaluated in randomized, double-blind, placebo-controlled studies for rheumatoid arthritis, Crohn's disease, and type 1 diabetes. The drug is investigational and not yet approved by regulatory authorities.
NNC0114-0006 has been studied in several completed trials. NCT01565408 was a Phase 1 dose-escalation study in rheumatoid arthritis. NCT01647451 was a Phase 2 efficacy trial in active rheumatoid arthritis. NCT01751152 was a Phase 2 trial in Crohn's disease. NCT02443155 was a Phase 2 proof-of-principle trial in newly diagnosed type 1 diabetes.
Yes, NNC0114-0006 was evaluated in a Phase 2 clinical trial (NCT02443155) in adults with newly diagnosed type 1 diabetes mellitus. The trial investigated the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function. The study enrolled 308 participants across multiple countries.
Yes, NNC0114-0006 was studied in a Phase 2 clinical trial (NCT01751152) for active Crohn's disease. The trial was randomized, double-blind, and placebo-controlled, enrolling 53 participants in the United States and several European countries. The study has been completed.